KBC Group NV increased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 78.2% during the 4th ...

BOSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...

BofA analyst Tazeen Ahmad raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $60 from $58 and keeps a Neutral rating on the shares after the company pre-announced Q4 and FY24 ...

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong ...

Rhythm Pharmaceuticals, Inc. (RYTM) shares soared 5.5% in the last trading session to close at $57.52. The move was backed by solid volume with far more shares changing hands than in a normal session.

Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) Inc on Wednesday, setting a price target of $43, which is... Morgan Stanley (NYSE ...

Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of ...

BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...